XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3

Segment Information (Tables)

9 Months Ended

Sep. 30, 2024

Segment Information [Abstract]

Schedule of Segment Information

		During the Three-Month Period Ended September 30, 2024
		Scours				Mastitis				Other				Total
Product sales		$	5,951,344			$	60,229			$	—			$	6,011,573
Costs of goods sold			4,364,950				63,069				—				4,428,019
Gross margin			1,586,394				(2,840	)			—				1,583,554
Product development expense			59,140				690,052				36,944				786,136
Sales and marketing expenses			699,584				144,461				—				844,045
Administrative expenses			—				—				528,267				528,267
Operating expenses			758,724				834,513				565,211				2,158,448
NET OPERATING INCOME (LOSS)		$	827,670			$	(837,353	)		$	(565,211	)		$	(574,894	)

		During the Three-Month Period Ended September 30, 2023
		Scours				Mastitis				Other				Total
Product sales		$	5,360,063			$	36,437			$	—			$	5,396,500
Costs of goods sold			4,095,164				34,455				—				4,129,619
Gross margin			1,264,899				1,982				—				1,266,881
Product development expenses			—				1,082,346				36,143				1,118,489
Sales and marketing expenses			641,682				175,804				—				817,486
Administrative expenses			—				—				514,952				514,952
Operating expenses			641,682				1,258,150				551,095				2,450,927
NET OPERATING INCOME (LOSS)		$	623,217			$	(1,256,168	)		$	(551,095	)		$	(1,184,046	)

		Scours				Mastitis				Other				Total
Total Assets as of September 30, 2024		$	23,672,583			$	16,798,955			$	3,977,335			$	44,448,873
Total Assets as of September 30, 2023		$	24,119,683			$	18,132,922			$	2,292,417			$	44,545,022
Depreciation and amortization expense during the three-month period ended September 30, 2024		$	346,430			$	319,815			$	19,682			$	685,927
Depreciation and amortization expense during the three-month period ended September 30, 2023		$	355,673			$	328,381			$	25,044			$	709,098
Capital Expenditures during the three-month period ended September 30, 2024		$	87,286			$	1,126			$	—			$	88,412
Capital Expenditures during the three-month period ended September 30, 2023		$	341,386			$	79,129			$	—			$	420,515

		During the Nine-Month Period Ended September 30, 2024
		Scours				Mastitis				Other				Total
Product sales		$	18,602,054			$	139,986			$	—			$	18,742,040
Costs of goods sold			13,487,348				145,294				—				13,632,642
Gross margin			5,114,706				(5,308	)			—				5,109,398
Product development expense			154,233				2,821,525				103,431				3,079,189
Sales and marketing expenses			2,224,836				405,089				—				2,629,925
Administrative expenses			—				—				1,661,838				1,661,838
Operating expenses			2,379,069				3,226,614				1,765,269				7,370,952
NET OPERATING INCOME (LOSS)		$	2,735,637			$	(3,231,922	)		$	(1,765,269	)		$	(2,261,554	)

		During the Nine-Month Period Ended September 30, 2023
		Scours				Mastitis				Other				Total
Product sales		$	12,253,555			$	122,153			$	—			$	12,375,708
Costs of goods sold			9,652,292				111,872				—				9,764,164
Gross margin			2,601,263				10,281				—				2,611,544
Product development expenses			2,543				3,220,075				105,779				3,328,397
Sales and marketing expenses			1,890,404				526,297				—				2,416,701
Administrative expenses			—				—				1,611,026				1,611,026
Operating expenses			1,892,947				3,746,372				1,716,805				7,356,124
NET OPERATING INCOME (LOSS)		$	708,316			$	(3,736,091	)		$	(1,716,805	)		$	(4,744,580	)

		Scours				Mastitis				Other				Total
Total Assets as of September 30, 2024		$	23,672,583			$	16,798,955			$	3,977,335			$	44,448,873
Total Assets as of September 30, 2023		$	24,119,683			$	18,132,922			$	2,292,417			$	44,545,022
Depreciation and amortization expense during the nine-month period ended September 30, 2024		$	1,027,711			$	958,260			$	59,221			$	2,045,192
Depreciation and amortization expense during the nine-month period ended September 30, 2023		$	1,020,909			$	969,666			$	64,066			$	2,054,641
Capital Expenditures during the nine-month period ended September 30, 2024		$	235,600			$	33,909			$	—			$	269,509
Capital Expenditures during the nine-month period ended September 30, 2023		$	1,038,033			$	773,136			$	—			$	1,811,169

		During the Year Ended December 31, 2023
		Scours				Mastitis				Other				Total
Product sales		$	17,293,933			$	177,736			$	—			$	17,471,669
Costs of goods sold			13,453,514				148,871				—				13,602,385
Gross margin			3,840,419				28,865				—				3,869,284
Product development expense			11,103				4,242,329				141,420				4,394,852
Sales and marketing expenses			2,447,137				641,078				—				3,088,215
Administrative expenses			—				—				2,134,295				2,134,295
Operating expenses			2,458,240				4,883,407				2,275,715				9,617,362
NET OPERATING INCOME (LOSS)		$	1,382,179			$	(4,854,542	)		$	(2,275,715	)		$	(5,748,078	)

		During the Year Ended December 31, 2022
		Scours				Mastitis				Other				Total
Product sales		$	18,411,949			$	154,558			$	1,455			$	18,567,962
Costs of goods sold			10,754,189				136,347				28,647				10,919,183
Gross margin			7,657,760				18,211				(27,192	)			7,648,779
Product development expenses			66,346				4,317,921				109,605				4,493,872
Sales and marketing expenses			1,871,926				1,318,107				—				3,190,033
Administrative expenses			—				—				2,263,817				2,263,817
Operating expenses			1,938,272				5,636,028				2,373,422				9,947,722
NET OPERATING INCOME (LOSS)		$	5,719,488			$	(5,617,817	)		$	(2,400,614	)		$	(2,298,943	)

		Scours				Mastitis				Other				Total
Total Assets as of December 31, 2023		$	24,735,413			$	17,827,839			$	1,244,850			$	43,808,102
Total Assets as of December 31, 2022		$	20,539,523			$	18,315,492			$	6,005,634			$	44,860,649
Depreciation and amortization expense during the year ended December 31, 2023		$	1,365,988			$	1,287,600			$	86,032			$	2,739,620
Depreciation and amortization expense during the year ended December 31, 2022		$	1,169,011			$	1,263,318			$	62,912			$	2,495,241
Capital Expenditures during the year ended December 31, 2023		$	1,096,819			$	795,694			$	—			$	1,892,513
Capital Expenditures during the year ended December 31, 2022		$	3,497,834			$	429,988			$	47,452			$	3,975,274

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration